ALCOX Stock Overview
Operates as an ophthalmology company in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Nicox S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.22 |
| 52 Week High | €0.49 |
| 52 Week Low | €0.14 |
| Beta | 0.89 |
| 11 Month Change | -16.73% |
| 3 Month Change | 20.86% |
| 1 Year Change | -46.06% |
| 33 Year Change | -92.82% |
| 5 Year Change | -94.46% |
| Change since IPO | -99.78% |
Recent News & Updates
Shareholder Returns
| ALCOX | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -3.9% | -7.7% | -0.3% |
| 1Y | -46.1% | -26.4% | -3.5% |
Return vs Industry: ALCOX underperformed the French Biotechs industry which returned -26.4% over the past year.
Return vs Market: ALCOX underperformed the French Market which returned -3.5% over the past year.
Price Volatility
| ALCOX volatility | |
|---|---|
| ALCOX Average Weekly Movement | 21.3% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALCOX's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALCOX's weekly volatility has increased from 12% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 28 | Gavin Spencer | www.nicox.com |
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Nicox S.A. Fundamentals Summary
| ALCOX fundamental statistics | |
|---|---|
| Market cap | €15.05m |
| Earnings (TTM) | -€23.28m |
| Revenue (TTM) | €4.64m |
3.2x
P/S Ratio-0.6x
P/E RatioIs ALCOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALCOX income statement (TTM) | |
|---|---|
| Revenue | €4.64m |
| Cost of Revenue | €10.21m |
| Gross Profit | -€5.57m |
| Other Expenses | €17.71m |
| Earnings | -€23.28m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | -120.07% |
| Net Profit Margin | -501.66% |
| Debt/Equity Ratio | 44.8% |
How did ALCOX perform over the long term?
See historical performance and comparison